![[headshot]](https://cdn.prod.website-files.com/68e9289a324a09160f2cdcc4/696671ced06ca1c345a319fd_Max.png)
Subscribe our newsletter to receive the latest blogs, case studies and publications.
SubscribeWhy 2026 Forces Pharma to Rethink Value, Pricing, and Evidence from Day Zero
EXECUTIVE SUMMARY
Pharma market access is undergoing a structural reset in 2026, driven by the convergence of U.S. policy enforcement (IRA), global pricing interdependence (MFN), payer behavior shifts, and the erosion of rebate-driven economics. Together, these forces are dismantling long-standing commercial models and replacing them with a system where value must be proactively designed, evidenced, and operationalized from the earliest stages of development. Organizations that continue to treat access as a downstream function will face accelerating revenue compression and restricted uptake, while those that integrate evidence, pricing, and access strategy from day zero will define the next era of competitive advantage.
---
For nearly three decades, pharma market access has operated within a relatively stable set of rules: pricing power was anchored in the U.S., rebates were the primary negotiation lever, regulatory approval was the milestone that determined commercial viability, and payer management was a downstream hurdle lumped into lifecycle management. In 2026, that model is breaking simultaneously, structurally, and irreversibly. What makes this moment different is not any single policy, but the convergence of forces that collectively redefine how value is assessed, priced, and accessed.
At the center is the transition from policy theory to policy reality. The Inflation Reduction Act has moved from abstract risk to operational impact, with the first 10 Medicare-negotiated drugs taking minimum discounts of 38%, generating an estimated $6 billion in annual savings for Medicare.1 This is not a pricing event, it is the establishment of a government-backed price anchor that will cascade across therapeutic areas, lifecycle strategies, and launch sequencing.
At the same time, the global pricing firewall that historically insulated the U.S. market is eroding. Most-Favored Nation has intertwined global and U.S. pricing strategy for the first time ever, creating a feedback loop between ex-U.S. and U.S. pricing decisions. Layer onto that a shifting geopolitical and regulatory environment (tariffs, domestic manufacturing incentives, and increased federal intervention), and the result is a market where pricing, supply chain, and access strategy can no longer be separated.
Meanwhile, the economic signals are flashing red. Median net launch prices rose 51% between 2022 and 2024, even as scrutiny intensifies and access tightens.2 In early 2026 alone, 872 branded drugs saw list price increases (median ~4%) despite aggressive policy efforts to reduce costs.3
Compounding this is a fundamental shift in how access is determined. Payers are no longer passive evaluators of regulatory approval; they are active architects of care pathways. Evidence expectations now exceed regulatory requirements, with increasing emphasis on comparative effectiveness, real-world outcomes, and total cost of care. Simultaneously, utilization management is becoming more sophisticated and entrenched, while PBM reform is actively dismantling the rebate-driven model that has defined U.S. market access for decades. In a post-rebate world, access will be dictated less by financial engineering and more by demonstrable, defensible value.
Taken together, these shifts create a simple but uncomfortable truth: traditional market access playbooks are now liabilities. Strategies built on late-stage evidence generation, siloed pricing decisions, and rebate maximization are misaligned with a system that requires early, integrated, and globally coherent value strategy.
Innovative organizations are already recalibrating. They are embedding access strategy into clinical development, designing trials with payer-relevant endpoints and real-world evidence from day one. They are stress-testing pricing under multiple policy scenarios (IRA, MFN, global reference pricing) and coordinating global launch sequencing accordingly. They are moving beyond formulary access to end-to-end access design, accounting for utilization management, site-of-care economics, and provider incentives. Most critically, they are reframing value not as a retrospective justification, but as a proactively engineered asset.
The stakes could not be higher. In an environment where government price-setting expands annually, intermediary economics are being rewritten, and global pricing is increasingly interconnected, the difference between success and failure will hinge on one capability: strategic coherence across evidence, pricing, and access from day zero. 2026 is not just another planning cycle, it is the year the rules changed. And for those still playing by the old ones, the consequences will be swift and unforgiving.
Market access is no longer a downstream checkpoint, but a primary driver of asset value. Winning in this environment requires a coordinated shift: designing, proving, and operationalizing value early, globally, and cross-functionally.
—
Max Klietmann is VP of Market Access Services at Alkemi, where he helps life sciences teams build payer-ready evidence and access strategies for launch and beyond.
---
Schedule a consultation below. Together, we’ll look at your situation and explore your value proposition. If we can help, we’ll explain how. If not, we’ll connect you with a partner who can.
